EMA Launches Pilot Program for Accelerated Approval of High-Risk Innovative Devices Targeting the €142 Billion EU Medical Device Market
Background and Purpose of the Pilot Program
The European Medicines Agency (EMA) has officially launched a new pilot program to promote the development of innovative medical devices (Breakthrough Devices) within the European Union, addressing diseases where existing treatments are insufficient. This initiative aims to mitigate the adverse effects of the recently strengthened European Medical Device Regulation (MDR), which has led to increased clinical and regulatory compliance costs and prolonged approval timelines for high-risk innovative medical devices. By providing close consultation from the early stages of product development, regulatory authorities demonstrate a strong commitment to expediting the introduction of high unmet medical needs technologies to the market without compromising safety standards.
Scope of Devices and Phased Implementation
The first phase (Phase 1a) of this pilot program prioritizes applications for Class III implantable devices (highest risk) and Class IIb devices (active medical devices for drug delivery or removal). The initial application deadline was May 22, 2026, and the EMA will select five innovative device projects by July 31, 2026, following a rigorous review by an expert panel. The pilot program is scheduled to run for a total of three phases by the end of 2027, with plans to expand the scope to include other high-value healthcare technology segments, such as in vitro diagnostic devices (IVD), based on the outcomes.
Impact on the Medical Device Industry and Venture Capital Market
This policy is a positive signal for global medtech companies and bio-focused venture capital (VC) firms that have struggled to overcome the stricter European Medical Device Regulation (MDR) certification hurdles. It significantly reduces early-stage regulatory risks in the high-risk medical device sector, which has historically faced higher investment risk compared to new drugs due to a lack of clinical data and regulatory uncertainty. In particular, the ability to receive scientific advice from the EMA expert panel from the early stages of development will help reduce trial-and-error in clinical design and provide a strong impetus for attracting large-scale follow-on investments from the seed stage.
Long-Term Institutionalization Prospects and Regulatory Harmonization
This pilot program serves as a key testbed for directly applying and optimizing the innovative device guidelines (MDCG 2025-9) published by the European Medical Device Coordination Group (MDCG) in December 2025. Ultimately, it will play a role in establishing the innovative device special approval clause (Article 52a) of the European Medical Device Regulation (MDR) amendment, which is currently under discussion in the European Parliament. This can be interpreted as a multifaceted strategy to enhance the regulatory attractiveness of the European market and safeguard its competitiveness as a global medtech hub, in response to the successful implementation of the Breakthrough Devices Program by the US Food and Drug Administration (FDA).
In the European medical device market, valued at €142.1 billion in 2024, this pilot program will revitalize investment in high-risk devices, which has been hampered by the strengthened European Medical Device Regulation (MDR). Class III and Class IIb developers can reduce clinical risks and significantly shorten regulatory approval timelines by receiving scientific advice from the European Medicines Agency (EMA). This complements the European market's appeal in competition with the US FDA's Breakthrough Devices Program and reduces the investment exit cycle for venture capital (VC). In the short term, attention should be paid to the first five projects to be selected by July 31, 2026. In the medium to long term, the accelerated approval track, which is expected to be institutionalized based on the results of the pilot program by 2027, is expected to accelerate the replacement of standard treatments in the European healthcare ecosystem.